Genmab is ending development of its acasunlimab candidate for lung cancer after a review of its portfolio. It is focusing instead on other oncology antibodies. Acasunlimab (GEN1046), a PD-L1x4-1BB bispecific antibody, was tested in the Phase III study GCT1046-06. This randomized, open-label study compares acasunlimab in combination with pembrolizumab (100 mg of acasunlimab and 400 mg of pembrolizumab every 6 weeks) versus docetaxel (75 mg/m² every 3 weeks). The study is for patients with stage IV metastatic non-squamous non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1% who have progressed after prior treatment with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy. The aim is to assess efficacy and safety as second- or third-line therapy. The study is ongoing in multiple centers including the Netherlands, Croatia, Estonia and Chile, with an estimated duration of up to 5 years for a participant. Genmab has assumed full responsibility for the development of acasunlimab without BioNTech.